Loading...

Oncolys BioPharma

DB:2OB
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2OB
DB
¥36B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Oncolys BioPharma Inc. engages in the research, development, manufacture, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
  • Oncolys BioPharma has significant price volatility in the past 3 months.
2OB Share Price and Events
7 Day Returns
-3%
DB:2OB
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
237.5%
DB:2OB
-10.2%
DE Biotechs
-6%
DE Market
2OB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oncolys BioPharma (2OB) -3% 15.1% 120.9% 237.5% 307.1% 373.7%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 2OB outperformed the Biotechs industry which returned -10.2% over the past year.
  • 2OB outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
2OB
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Oncolys BioPharma's competitors could be found in our database.

Value

 Is Oncolys BioPharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Oncolys BioPharma. This is due to cash flow or dividend data being unavailable. The share price is €22.24.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oncolys BioPharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oncolys BioPharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2OB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥-104.55
TSE:4588 Share Price ** TSE (2019-04-18) in JPY ¥2685
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oncolys BioPharma.

DB:2OB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4588 Share Price ÷ EPS (both in JPY)

= 2685 ÷ -104.55

-25.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncolys BioPharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Oncolys BioPharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Oncolys BioPharma's expected growth come at a high price?
Raw Data
DB:2OB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -25.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
6.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oncolys BioPharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oncolys BioPharma's assets?
Raw Data
DB:2OB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥217.38
TSE:4588 Share Price * TSE (2019-04-18) in JPY ¥2685
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:2OB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4588 Share Price ÷ Book Value per Share (both in JPY)

= 2685 ÷ 217.38

12.35x

* Primary Listing of Oncolys BioPharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncolys BioPharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Oncolys BioPharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oncolys BioPharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Oncolys BioPharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oncolys BioPharma expected to grow at an attractive rate?
  • Unable to compare Oncolys BioPharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Oncolys BioPharma's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Oncolys BioPharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2OB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2OB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 6.1%
DB:2OB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 23.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2OB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2OB Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 550 -940 -950 1
2020-12-31 350 -1,140 -1,150 1
2019-12-31 550 -940 -950 1
DB:2OB Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 169 -1,188 -1,234
2018-09-30 319 -1,213
2018-06-30 300 -1,194 -1,214
2018-03-31 248 -1,160
2017-12-31 229 -1,097 -1,091

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oncolys BioPharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Oncolys BioPharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2OB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Oncolys BioPharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2OB Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -71.20 -71.20 -71.20 1.00
2020-12-31 -86.20 -86.20 -86.20 1.00
2019-12-31 -71.20 -71.20 -71.20 1.00
DB:2OB Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 -104.55
2018-09-30 -107.52
2018-06-30 -110.38
2018-03-31 -108.39
2017-12-31 -106.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Oncolys BioPharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Oncolys BioPharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oncolys BioPharma has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Oncolys BioPharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oncolys BioPharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oncolys BioPharma does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Oncolys BioPharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oncolys BioPharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oncolys BioPharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oncolys BioPharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2OB Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 168.55 -1,233.85 1,294.78
2018-09-30 318.53 -1,213.29 1,386.89
2018-06-30 299.68 -1,213.86 1,370.57
2018-03-31 247.63 -1,159.54 1,293.49
2017-12-31 229.14 -1,090.70 1,235.97

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oncolys BioPharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Oncolys BioPharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oncolys BioPharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oncolys BioPharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oncolys BioPharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Oncolys BioPharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oncolys BioPharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oncolys BioPharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Oncolys BioPharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oncolys BioPharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oncolys BioPharma Company Filings, last reported 3 months ago.

DB:2OB Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 2,901.15 401.58 2,463.14
2018-09-30 2,856.90 411.87 2,389.33
2018-06-30 2,290.16 422.67 1,852.16
2018-03-31 2,596.83 443.71 2,248.36
2017-12-31 2,931.89 454.74 2,867.51
  • Oncolys BioPharma's level of debt (13.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Oncolys BioPharma's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oncolys BioPharma has sufficient cash runway for 2.1 years based on current free cash flow.
  • Oncolys BioPharma has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 7.8% each year.
X
Financial health checks
We assess Oncolys BioPharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oncolys BioPharma has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Oncolys BioPharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oncolys BioPharma dividends.
If you bought €2,000 of Oncolys BioPharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oncolys BioPharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oncolys BioPharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2OB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2OB Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oncolys BioPharma has not reported any payouts.
  • Unable to verify if Oncolys BioPharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oncolys BioPharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oncolys BioPharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Oncolys BioPharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oncolys BioPharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oncolys BioPharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Oncolys BioPharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yasuo Urata
AGE 63
TENURE AS CEO 15.1 years
CEO Bio

Mr. Yasuo Urata, M.Sc. has been President and Chief Executive Officer of Oncolys BioPharma Inc. since March 2004. Mr. Urata served various executive functions at Japan Tobacco pharmaceutical division (JT Pharmaceutical), including Director of R&D Planning. During the time of JT from 1994 to 2004, he launched the innovative HIV drug, Viracept® with Agouron and led many drug development projects such as GVAX project with Cell Genesys and the cancer vaccine project with Corixa. He served as clinical project leader mainly for cardiovascular and central nerve system fields. He has been Representative Director of Oncolys BioPharma Inc. since March 2004. He serves as Director of Tacere Therapeutics, Inc. Mr. Urata holds B.S. and M.S. from Kyoto Pharmaceutical University.

CEO Compensation
  • Insufficient data for Yasuo to compare compensation growth.
  • Insufficient data for Yasuo to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Oncolys BioPharma management team in years:

6
Average Tenure
55
Average Age
  • The average tenure for the Oncolys BioPharma management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Yasuo Urata

TITLE
CEO, President & Representative Director
AGE
63
TENURE
15.1 yrs

Yasunari Kashihara

TITLE
Vice President of Business Development & Director
AGE
53
TENURE
11.1 yrs

Keiji Yoshimura

TITLE
Vice President & Director
AGE
63
TENURE
6.1 yrs

Takashi Kamitani

TITLE
Vice President & Director
TENURE
2.1 yrs

Naoki Kobayashi

TITLE
Vice President & Adjunct Director
AGE
55
TENURE
1.4 yrs

Yasushi Rokutanda

TITLE
Special Advisor
AGE
54
TENURE
2.1 yrs

Toshiyoshi Fujiwara

TITLE
Special Advisor
TENURE
6 yrs
Board of Directors Tenure

Average tenure and age of the Oncolys BioPharma board of directors in years:

6.1
Average Tenure
63
Average Age
  • The tenure for the Oncolys BioPharma board of directors is about average.
Board of Directors

Yasuo Urata

TITLE
CEO, President & Representative Director
AGE
63
TENURE
15.1 yrs

Yasunari Kashihara

TITLE
Vice President of Business Development & Director
AGE
53
TENURE
11.1 yrs

Keiji Yoshimura

TITLE
Vice President & Director
AGE
63
TENURE
6.1 yrs

Takashi Kamitani

TITLE
Vice President & Director
TENURE
2 yrs

Naoki Kobayashi

TITLE
Vice President & Adjunct Director
AGE
55
TENURE
2.1 yrs

Fumio Urano

TITLE
External Director
AGE
75
TENURE
6.1 yrs

Shiro Ohki

TITLE
External Auditor
AGE
75
TENURE
7.6 yrs

Katsufusa Tachiya

TITLE
Corporate Auditor
TENURE
2.1 yrs

Michihiro Yamaoka

TITLE
Outside Auditor
AGE
52
TENURE
2.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Oncolys BioPharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oncolys BioPharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Oncolys BioPharma Inc. engages in the research, development, manufacture, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents. The company’s product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in Phase I clinical stage for the treatment of esophageal cancer and hepatocellular carcinoma, as well as in Phase II clinical trial for the treatment of melanoma; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical study for the treatment of solid tumors, as well as in pre-clinical study for ophthalmic use. It also offers OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that is in Phase II clinical trial for the treatment of HIV infection. In addition, the company develops TelomeScan (OBP-401 and OBP-1101) for detecting living circulating tumor cells in blood from cancer patients. Oncolys BioPharma Inc. was founded in 2004 and is headquartered in Tokyo, Japan.

Details
Name: Oncolys BioPharma Inc.
2OB
Exchange: DB
Founded: 2004
¥285,368,436
13,394,200
Website: http://www.oncolys.com
Address: Oncolys BioPharma Inc.
Toranomon Towers Office,
4-1-28 Toranomon,
Tokyo,
105-0001,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4588 Common Shares The Tokyo Stock Exchange JP JPY 06. Dec 2013
DB 2OB Common Shares Deutsche Boerse AG DE EUR 06. Dec 2013
Number of employees
Current staff
Staff numbers
33
Oncolys BioPharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:00
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/13
Last earnings filing: 2019/02/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.